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Abstract
Introduction: Lymphatic malformations are benign anomalies derived from the abnormal development of lymphatic channels.
Usually asymptomatic, they can cause compression on adjacent structures or present acute complications (bleeding or infection).
Small asymptomatic lesions can be conservatively managed since the possibility of spontaneous regressions is described, while
symptomatic lesions require active management. Less invasive therapeutic options are now preferred instead of surgery
(sclerotherapy, laser therapy). However, there are not uniform therapeutic protocols.
CaseReport:We present the case of a term newborn with an abdominal cystic lymphangioma extending from the umbilical to the
right inguinal area, reaching the medial surface of the right tight. Despite its large dimensions, which classically request surgical
management, the patient was by chance asymptomatic, and the mass did not determine compression on the surrounding organs.
Therefore, conservative management was tried, and a close clinical and radiological follow-up was started. This approach permitted
a spontaneous regression of the mass and to avoid major surgical intervention.
Conclusion:Our purpose is to underline the possibility of conservative management of the major multicystic masses and to focus
on less invasive therapeutic options, like sclerotherapy, oral therapy, and laser therapy.
Abbreviations: CT = computed tomography, LM = lymphatic malformation, MRI = magnetic resonance imaging, US =
ultrasound, VEGF = vascular endothelial growth factor.
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1. Introduction Cutaneous manifestations are often the main clue that revealsVascular malformations are described as a group of anomalies
due to a disembryogenetic process, which can result in arterial,
venous, capillary, lymphatic, or combined malformations.[1]
Lymphatic malformations (LMs) are considered to be rare and
benign anomalies caused by the defective embryological
development of the primordial lymphatic structures. They consist
of dilated lymphatic channels forming multiple cysts. LMs can be
classiﬁed into macrocystic, microcystic, or mixed cystic lesions.[1]
Macroscopically, they can give rise to the formation of masses
of different sizes that depending on their location can be variably
appreciated through deep palpation as soft, non-pulsatile, and
painless masses.[2] The overlying skin is normal, but it can also
have a bluish hue or contain pink vesicles, that can appear similar
to capillary malformations, angiokeratomas, or angiomas.Editor: Giovanni Li Volti.
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1the presence of further complex underlying condition, with
deeper lesions involving different tissue planes.[3]
The cervicofacial region is most affected (48%). LMs can also
be found in the trunk, axilla, and extremities (42%). The
mediastinal and abdominal locations are rare (10%). Half of
these lesions are typically present at birth and are often diagnosed
prenatally. Nevertheless, 90% are diagnosed at 2 years old. Only
a minority of cases cannot be detected due to their deep
localization or absence of symptoms.[2]
Here, we discuss the case of a term newbornwith an abdominal
cystic lymphangioma, diagnosed through prenatal ultrasound
screening, and its management.2. Case report
2.1. Presenting concerns
A female caucasian baby was born by cesarean section at 39
weeks of gestation to a 37-year-old mother. Family medical
history was unremarkable. The pregnancy had a normal course
until 32 weeks of gestation when an obstetric ultrasound (US)
showed the presence of a cystic abdominal mass of about 3cm in
diameter, localized between the bladder and the umbilicus, which
was suggestive of an urachal cyst without other structural
alterations of the urinary apparatus. At birth, APGAR score was
9/10 and birth weight 3200g.2.2. Clinical ﬁndings
At physical examination, a vascular lesion (4cm4cm) was
detected in the right lower abdominal quadrant. The presence of a
soft suprapubic mass was also appreciated, without alterations of
the overlying skin. The patient was otherwise asymptomatic.
Amodeo et al. Medicine (2017) 96:8 MedicineThe dermatologist conﬁrmed the diagnosis of complex
vascular malformation: it consisted in a venocapillary superﬁcial
lesion associated with multicystic lymphangiomatous lesions in
the subcutaneous tissues, involving the right lower abdomen and
the homolateral inguinal area and tight. Also, a small angioma-
tous lesion of the right ﬁrst toe with no dysmetria of the affected
limb was detected at physical examination.2.3. Timeline
Table 1 summarizes the main clinical and radiologic ﬁndings in
our patients, which led to the diagnosis of multicystic
lymphangioma, and the major steps in the management and
follow-up.Figure 1. Abdominal ultrasound scan showing subcutaneous cysts. 1:
maximum diameter 3.1cm, 2: minimum diameter 0.5cm.2.4. Diagnostic focus and assessment
On the second day of life the abdominalUSwas performed, andno
congenital urachus abnormalities were detected, but rather some
hypo-anechoic cysts of about 3.10.5cm that extended from the
umbilical to the right inguinal area, reaching the medial surface of
the thigh, with a little extremity just above the homolateral knee
(Fig. 1). TheDoppler technique showed somevascular signals from
the adipose tissue where these cystic lesions were located. A
magnetic resonance imaging (MRI) scan with contrast was then
performed. In consideration of the age of the patient, sedation was
needed during the exam. At MRI, several lacunas with cystic
appearance were observed in the subcutaneous adipose tissue of
the right lower abdomen. These structures had variable size
(maximum 3cm of diameter) and were hypointense in T1 and
hyperintense in T2 sequences. Cysts seemed to be restricted to the
subcutaneous tissues since no signals of muscular or abdominal
cavity involvement were evident. After the intravenous contrast
administration, no signiﬁcant enhancement of the cysts’ content
was seen. All MRI characteristics conﬁrmed the diagnosis of
multicystic lymphangioma (Fig. 2).Table 1
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22.5. Therapeutic focus and assessment
As surrounding abdominal organs were not involved and
compressive complications on adjacent organs were not present,
given the possibility of spontaneous regression of the lesion, a
“wait and see” strategy was adopted, and the patient was closely
monitored through a multidisciplinary follow-up program.
2.6. Follow-up and outcomes
A size reduction and progressive discoloration were macroscop-
ically appreciated, and progressive regression was conﬁrmed
through serial US evaluations.etection of an abdominal cystic mass localized between the bladder and the
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omatic. Given the risk of bleeding or ulceration of the superﬁcial angiokeratomas,
the best treatment choice
Figure 2. MRI scan with contrast in the coronal plane. Cysts can be observed
in the subcutaneous adipose tissue of the right lower abdomen and right thigh.
MRI=magnetic resonance imaging.
Amodeo et al. Medicine (2017) 96:8 www.md-journal.comSixteen months later, the presence of a new cystic formation (3.6
cm2.1cm1.9cm) with irregular morphology and corpuscular
contentwasdetectedat theUSscan, referable toan intracysticbleeding.
Since the patient was asymptomatic and no other complications were
detected, the conservative approach was carried on.
During the following months, some millimetric angiokerato-
mas developed.
Almost 3 years later, the cystic lymphangioma appears
signiﬁcantly reduced in extension, and the cysts now have a
maximum diameter of 0.8 to 1cm. No alterations or compres-
sions of adjacent organs were present. The patient is 3 years old,
has normal neurodevelopment and does not have any abdominal
disturbances. No compression on adjacent organs nor dysmetria
at the inferior limbs is present.
However, given the risk of bleeding or ulceration of the
superﬁcial angiokeratomas, pulsed dye laser seems now the best
treatment choice.[4,5]3. Discussion
Intra-abdominal cystic lymphangiomas are a rare type of
lymphangioma. Their clinical manifestations are highly poly-
morphic. A large tumor volume usually appears as a palpableTable 2
Therapeutic scheme of the principal pharmacological agents used fo
Sclerotherapy
Drug Dos
Bleomycin 15mg/m2 per dose 2 times/wk
Doxycycline 100mg powder in 5mL water-solub
OK-432/Picibanil Concentration of 0.01mg/mL; maxim
Oral therapy
Drug Dose
Sildenaﬁl 1mg/kg per dose 3 times/d
Propranolol 2mg/kg/die
Sirolimus 0.8mg/m2 per dose 2 times/d; target
3mass which can cause abdominal pain (in older patients), an
increase in waist circumference and, in severe cases, acute
abdominal emergencies like intestinal obstruction or volvulus.
The two most common acute complications are bleeding and
infection. Bleeding is typically intra-cystic with a consequent
bluish discoloration of the LM, swelling, and pain. Infection can
progress rapidly to sepsis and hospitalization is often necessary to
provide an adequate intravenous antimicrobial therapy.[6]
As associated manifestation, superﬁcial angiokeratomas can
develop which can easily bleed or ulcerate under mechanical
stimuli.[4]
Ultrasound examination is an excellent modality to detect
these lesions, and it is the gold standard to monitor their clinical
evolution. The computed tomography (CT) andMRI scanner are
a valuable initial diagnostic tool. However, MRI is the most
informative exam. Histologic conﬁrmation of LMs is rarely
necessary.
The goal of LM management and treatment is to maintain the
functionality, to preserve the aesthetic integrity, and to control
associated symptoms. Given the large heterogeneity of LM,
therapy should always be individualized.
Surgical excision has been historically considered the treatment
of choice for macrocystic/unicameral LMs.[7] It consists in the
complete resection of the lesion but presents a high complication
rate (in particular bleeding, iatrogenic damages, and deformity)
without guaranteed success. In multicystic/combined LMs,
resection is usually incomplete since lesions involve several
tissue planes, with a recurrence rate of 35% to 64%, which
decreases to 17% to 22% in case of total excision.[8] For these
reasons, surgical excision is reserved for selected cases such as
well-localized and unicameral LMs for which it may result to be
curative, obstructing masses, which compromise vital functions,
complicated or symptomatic macrocystic/combined LMs unsuit-
able for sclerotherapy.[6]
Today, less invasive therapeutic options are preferred (Table 2).
Small asymptomatic lesions, with a variable frequency up to
45%, spontaneously regress and can be carefully monitored.
Therefore, surgery is usually postponed as much as possible, at
least until the age of 18 to 24 months.[6,9–11]
Sclerotherapy has become the main therapeutic choice. It
consists of US-guided percutaneous cysts aspiration and subse-
quent injection of a proinﬂammatory substance (such as
doxycycline, bleomycin, OK-432/Picibanil), which cause scarring
of the cyst walls (for the therapeutic scheme, see the Table 2).
Sclerotherapy has a high success rate with lower recurrence and
complication rates, especially for microcystic LMs. The most
common complication of sclerotherapy is skin ulceration
(<5%).[12]r the treatment of lymphatic malformations.
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serum levels 10–15ng/mL Adams et al[18]
Amodeo et al. Medicine (2017) 96:8 MedicineDoxycycline is the most common sclerosant agent used to treat
LMs, with 70% to 100% response rate and 10% to 14%
complication rate. Pain is the main side effect. Other systemic
complications are hemolytic anemia, metabolic acidosis, hypo-
glycemia, and delayed neural complications.[12]
There have been reported deaths related to bleomycin
sclerotherapy, and because of its known risk of pulmonary
ﬁbrosis, it is a less attractive sclerosing agent, although very
effective.[2,13]
OK-432 has >80% success rate but causes systemic reactions
such as fever, malaise, anorexia and cannot be administered in
children with penicillin allergy.[2,14]
Laser treatment with the carbon dioxide or the Nd:YAG is
reserved for associated superﬁcial cutaneous/mucosal vesicles,
especially in the management of acute bleeding in cutaneous or
subcutaneous lesions.[15] For superﬁcial lymphatic malforma-
tions at high risk of bleeding, such as angiokeratomas, pulsed dye
laser might be considered as a treatment option.[4,5]
New therapies continue to emerge for the treatment of
LMs. Sildenaﬁl, sirolimus, and propranolol are three oral
medications that have been reported to be effective in the recent
literature.
Case reports show that sildenaﬁl can decrease LM size and
alleviate associated symptoms.[16] Propranolol is routinely used
for infantile hemangiomas, recent studies have shown its efﬁcacy
in the treatment of some LMs, although some patients do not
respond to treatment.[17] Sirolimus is an efﬁcacious and safe
treatment for complex vascular anomalies, even when refractory
to other treatment. Sirolimus is an mTOR inhibitor and exerts
antiangiogenic activity in tumors by impairing vascular endothe-
lial growth factor (VEGF) production. It has been successfully
used to treat vascular anomalies in children and newborn.
Described side effects are mucositis, hypercholesterolemia,
headache, elevation of transaminases, neutropenia.[18]
New surgical techniques have also been utilized in the
treatment of LMs. Ultrasound-guided liposuction was shown
to be efﬁcient and has been used in conjunction with
sclerotherapy to treat multicystic LMs better.[19]
In this clinical case, the patient had a voluminous multicystic
malformation involving the abdominal subcutaneous tissues
from the mesogastric region to the right inguinal area, reaching
the medial surface of the homolateral thigh. In such extended and
multicystic lesions, surgical excision is frequently incomplete, and
this implicates high risk of failure and high recurrence rate.
Moreover, special considerations have to be taken into account
for the neonatal patient, for example, the risks related to total
anesthesia and the need for mechanical ventilation, the risk of
major blood loss, infections, and iatrogenic injury. Pain control is
also challenging. The postoperative scar and deformity after
removal of the LM should be weighted. For all these reasons, we
would have considered surgery only in case of compressive,
symptomatic or complicated masses, trying to postpone the
intervention as much as possible.[6,8]
In our patient, the lesions did not involve primary structures
and did not cause compressive complications on adjacent organs.
This favorable situation permitted us to choose a conservative
management (“watchful waiting”), hoping in the spontaneous
regression of the cysts, as suggested by the recent literature.[11,20]
Since it was a complex malformation, a close clinical and
radiological follow-up was needed. As we expected, serial
ultrasounds showed a progressive reduction of the cysts. Bleeding
occurred just once, with no other complications associated. The4patient remained asymptomatic for almost 2 years, and then
some millimetric angiokeratomas developed. Angiokeratomas
are superﬁcial vascular anomalies with a tendency to bleeding
and ulceration as a consequence of mechanical or traumatic
stimuli. At 3 years of age, the patients started to attend the
nursery school, and some minimal bleeding occurred. To avoid
major complications, we decided to consider a non-invasive
treatment. Although CO2 laser can achieve successful results, it
has some disadvantages, such as the requirement of anesthesia
and the risk of scarring.[21] As reported in previous cases, pulsed
dye laser is used to treat vascular lesions and lymphangioma
circumscriptum with a lower risk of complication such as
pigmentation or scarring.[4,5,22] For these reasons, we opted for
pulsed dye laser to treat the cutaneous manifestations and prevent
local complications.
This clinical case demonstrates that, if the mass does not
compromise vital function or undergoes acute complications, a
conservative approach is a reasonable choice in the management
of large and complex LMs. This approach permits to take
advantage of spontaneous regression in most cases and to
consider less invasive therapeutic options later.References
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